COMMON QUESTIONS
Semaglutide & Tirzepatide — Research FAQ
Cited answers to the most common questions about incretin-based metabolic peptides.
What is semaglutide?
Semaglutide is a 31-amino-acid GLP-1 receptor agonist — an engineered version of the gut incretin hormone glucagon-like peptide-1. Structural modifications (an Aib substitution at position 8 and a C18 fatty-acid albumin-binding arm) extend its half-life to roughly seven days, enabling once-weekly dosing. It is FDA-approved for type 2 diabetes, obesity, cardiovascular risk reduction, and chronic kidney disease in type 2 diabetes.
What is semaglutide used for?
In clinical trials and approved labelling, semaglutide has been studied for: lowering blood glucose and HbA1c in type 2 diabetes; reducing body weight in adults with overweight or obesity; reducing major adverse cardiovascular events in adults with established cardiovascular disease [3]; slowing progression of chronic kidney disease in type 2 diabetes [2]; and (as of 2025) treating metabolic dysfunction-associated steatohepatitis (MASH). All uses listed are from published trials or approved indications — not off-label recommendations.
How does semaglutide work?
Semaglutide activates GLP-1 receptors on pancreatic beta cells (stimulating insulin secretion in proportion to blood glucose), alpha cells (suppressing glucagon), and gastric smooth muscle (slowing emptying). Its weight effect is primarily central: rodent imaging studies show it directly accesses the brainstem area postrema, hypothalamic arcuate nucleus, and parabrachial nucleus, activating satiety neurons and inhibiting hunger neurons, reducing food intake without reducing energy expenditure [6].
How does semaglutide work for weight loss?
The weight-loss mechanism is predominantly central appetite suppression rather than metabolic acceleration. Semaglutide reaches brain appetite circuits directly: animal studies document access to the arcuate nucleus and area postrema, where it activates anorexigenic (anti-hunger) POMC/CART neurons and inhibits orexigenic (pro-hunger) NPY/AgRP neurons [6]. People eat less — and report reduced cravings, smaller portions, and loss of interest in high-calorie food — without an increase in energy expenditure. The STEP 1 trial found -14.9% mean body weight change at 68 weeks versus -2.4% with placebo [4].
What is tirzepatide?
Tirzepatide is a 39-amino-acid synthetic peptide that activates both the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R) simultaneously — the first approved dual incretin agonist, also called a twincretin or dual incretin mimetic. It is FDA-approved for type 2 diabetes (May 2022), chronic weight management (November 2023), and moderate-to-severe obstructive sleep apnea in adults with obesity. Its mechanism and approvals are summarised in the StatPearls reference [8].
How does tirzepatide work?
Tirzepatide activates two receptor targets with one molecule: GIPR and GLP-1R. GLP-1R activation produces the same downstream effects as semaglutide — glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and appetite reduction via central circuits. Adding GIPR activation appears to amplify the metabolic effect: in head-to-head trials, tirzepatide produced significantly greater HbA1c reduction and weight loss than selective GLP-1 agonism at comparable doses [11]. The exact mechanistic contribution of each receptor to the overall effect is still being characterised in research.
What does tirzepatide do in the body?
Tirzepatide enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon, slows gastric emptying, reduces appetite and food intake, and (in trials) produces substantial body-weight reduction [10]. It also appears to improve several downstream metabolic markers — lipids, blood pressure, insulin sensitivity — documented in the SURPASS and SURMOUNT trial programmes. In SURMOUNT-1, the highest studied dose produced a mean weight change of -20.9% versus -3.1% with placebo over 72 weeks [10]. Secondary cardiovascular and metabolic outcomes from dedicated tirzepatide outcome trials are under investigation.
What is tirzepatide used for?
Tirzepatide is FDA-approved for type 2 diabetes mellitus, chronic weight management in adults with obesity or overweight plus a weight-related condition, and moderate-to-severe obstructive sleep apnea in adults with obesity [8]. Published phase 3 trials document glycaemic efficacy (SURPASS programme) and weight-management efficacy (SURMOUNT programme). It is a prescription-only medicine; this desk describes its research profile, not access or sourcing.
Which produces more weight loss — semaglutide or tirzepatide?
In the head-to-head SURMOUNT-5 phase 3b trial (n=751, 72 weeks, adults with obesity without type 2 diabetes), tirzepatide at maximum tolerated dose produced -20.2% mean weight loss versus -13.7% for semaglutide at maximum tolerated dose — a statistically significant difference (P<0.001) [1]. In SURPASS-2 (type 2 diabetes, 40 weeks), tirzepatide was superior to semaglutide 1 mg at all three studied doses for both HbA1c reduction and body-weight loss [11]. The clinical significance depends on individual context; this desk reports trial data only.
What are the main side effects of these compounds?
Both share a similar GI-dominant adverse-effect profile driven by their shared mechanism of slowing gastric emptying. Nausea is the most frequently reported adverse effect for both — affecting roughly one-third of patients on semaglutide [5] and 25–50% of users in community reports for tirzepatide. Constipation and diarrhea are common to both. Gallbladder and biliary disease risk is increased for both, linked to the rate of weight loss [5][9]. Both carry a thyroid C-cell boxed warning based on rodent data [5][8]. Both show lean-mass loss alongside fat loss in body-composition substudies.
Do these peptides cause lean-mass or muscle loss?
Body-composition substudies from both programmes show a meaningful fraction of total weight lost is lean mass. STEP DXA substudies document this for semaglutide; SURMOUNT-1 DXA analysis found approximately 25% of lost weight was lean mass with tirzepatide. A broader systematic review across incretin trials put the median muscle-attributable share of weight loss near 28%. The clinical significance is under investigation; the downstream sarcopenia concern is mechanistically reasoned, not yet established as a measured functional outcome.
What happens if you stop taking these compounds?
Both compounds produce substantial weight regain after discontinuation. The STEP 1 trial extension reported a mean regain of approximately 11.6 percentage points within one year of stopping semaglutide, with cardiometabolic improvements reverting toward baseline. SURMOUNT-4 demonstrated that participants switched from tirzepatide to placebo regained weight while those continuing treatment kept losing. This pattern frames both agents as chronic-treatment therapies rather than short-course interventions.